Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Medicine and Dentistry
Childhood Cancer
100%
Systematic Review
37%
Anthracycline
31%
Adolescence
28%
Malignant Neoplasm
27%
Ganglioneuroblastoma
24%
Late Effect
21%
High Dose Chemotherapy
16%
Radiation Therapy
16%
Randomized Controlled Trial
14%
Cancer in Young Adults
14%
Adverse Event
13%
Chemotherapy
13%
Congestive Heart Failure
12%
Prevalence
12%
Overall Survival
10%
Echocardiography
10%
Cardiotoxicity
10%
Hematopoietic Cell
10%
Event Free Survival
9%
Platinum
9%
Ewing Sarcoma
9%
Hearing Impairment
8%
Pediatrics
8%
Autologous Hematopoietic Stem Cell Transplantation
8%
Cell Transplantation
8%
Hazard Ratio
7%
Heart Function
7%
Quality of Life
7%
Myocardial Disease
6%
Diseases
6%
Oncology
6%
Tretinoin
6%
Anticarcinogen
6%
Cisplatin
5%
Cardiology
5%
Recurrent Disease
5%
Cohort Analysis
5%
Biological Marker
5%
Keyphrases
Anthracyclines
44%
Childhood Cancer
38%
Heart Failure
22%
Late Effects
18%
Cardiotoxicity
16%
High-dose Chemotherapy
16%
High-risk Neuroblastoma
16%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
16%
Survivors
15%
Older Adults
14%
Risk Factors
14%
Randomized Controlled Trial
13%
Children with Cancer
11%
Cardiac Dysfunction
11%
After childhood
10%
Preadolescent children
10%
95% Confidence Interval
9%
Overall Survival
9%
Echocardiography
9%
Cancer Guidelines
9%
Dutch
8%
Event-free Survival
8%
Ewing Sarcoma
8%
High Risk
7%
Doxorubicin
7%
Cumulative Incidence
6%
Cochrane Review
6%
Anthracycline-induced Cardiotoxicity
6%
Mitoxantrone
6%
Hazard Ratio
6%
Radiotherapy
6%
Surveillance Guidelines
6%
Retinoic Acid
6%
Infusion Duration
5%
Young Adult Cancer Survivors
5%
Global Longitudinal Strain
5%
Ifosfamide
5%
MEDLINE
5%
Anthracycline Chemotherapy
5%
Embase
5%
Pharmacology, Toxicology and Pharmaceutical Science
Childhood Cancer
47%
Anthracycline
46%
Cardiotoxicity
25%
Malignant Neoplasm
25%
Congestive Heart Failure
21%
Randomized Controlled Trial
12%
Overall Survival
11%
Chemotherapy Regimens
10%
Neuroblastoma
10%
Doxorubicin
7%
Razoxane
6%
Adverse Event
6%
Mitoxantrone
6%
High Dose Chemotherapy
6%
Anticarcinogen
6%
Event Free Survival
6%
Progression Free Survival
5%
Prevalence
5%
